This research study involves an experimental drug (NST_001) and a delivery system. The main purpose of this research study is to investigate the safety of NST-001, delivered directly to the inner ear for the treatment of tinnitus.

I dont know if if the right place to place this but still i'm going ahead
There are now trials for a drug named NST-001. I don't know if some has already tried it but they are searching for people to participate in Belgium, France.

Very interesting, I wonder what is the substance in NST-001. Probably also nmda antagonist to suppress excessive glutamate. The whole thing looks similar to AM-101. If only there was some other way to administer the drug other than middle ear injection

Another thing that makes me wonder is 10-year limit inclusion criteria. With AM-101 it is 3 months. I have a feeling those time limits are completely arbitrary...

EDIT: this study hasn't been updated for almost a year now, I wonder what happened.

If you ask me they can administer the drug from any point or hole they want on me as long it becomes quiet in my ears.

Now what I read somewhere they did trials before and they searched for people before who had TT maximum 1 year, and i guess they want to see if they get any success with people who have TT for longer time.

Now they must have some results since the study started 2009 and was supposed to end at december 2012.

An update, and not good one for us who have tinnitus more then a year. Suck =(

A new drug can help ease the discomfort of tinnitus when pumped into the inner ear, according to a recent study.

A powerful new medicine, named NST-001, has proven to be effective in calming the overactive nerves in the inner ear thought to cause tinnitus. Directly pumped into the inner ear, the drug could block the production of excessive glutamate, a brain chemical, which hyperactivates nerve cells. Such hyperactivity occurs, for example, when hearing is damaged in some way, for instance by exposure to loud noise.At the research stage

Animal research has found that when the drug was placed in the ear, it reduces the sounds of tinnitus. And in a small pilot study on human volunteers in Germany, the majority of patients given the drug reported a significant reduction of tinnitus.

Dr Ralph Holme, director of Biomedical Research at the Royal National Institute for the Deaf, says: “In recent years, there has been research into a number of drugs which aim to reduce the hyperactivity in the brain associated with tinnitus. This particular study is interesting, as it is also testing a new way of administering a drug by pumping it straight into the inner ear.” Development of a pump

Studies have however also shown that the effect of the drug is only present during the treatment. After which, the tinnitus returns to the previous levels. The researchers are therefore focused on developing a fully integrated drug pump. The pump must have an internal reservoir that will administer the drug for more than a year, after which it will be refilled through the skin via a minor surgical procedure.

This new treatment is primarily meant for patients who have had tinnitus for less than a year, as the treatment must act during the phase when the tinnitus is still only linked to disorders in the internal ear. As of yet, it is unknown whether it will work in well-established tinnitus.

OTO-311 is a sustained-exposure formulation of the potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine. Clinical studies, including pilot studies conducted with gacyclidine, support the use of NMDA receptor antagonists as potential treatments for tinnitus. In 2013, Otonomy acquired certain assets and rights to intellectual property related to the use of gacyclidine for the treatment of tinnitus from an affiliate of NeuroSystec Corporation, a company founded by serial entrepreneur Alfred Mann.